Fourteen Democratic members of Congress have written Gilead Sciences to ask that the company reasonably price its yet-to-be-approved AIDS drug "Quad". The once-a-day first-line AIDS treatment, which contains four medications, was recommended for approval by a Food and Drug Administration advisory panel. The congressional representatives fear that Gilead may charge as much as $34,000 per patient per year for Quad, which could further strain state AIDS funding programs.View Full Article
Although Gilead froze prices through 2013 for drugs provided to AIDS Drug Assistance Programs (ADAPs), the company increased prices in the commercial market, raising costs for privately insured patients and those on Medicare.
Comment by: michael
Fri., Aug. 24, 2012 at 3:02 am UTC
rather silly that "the" government is begging these scumbags to price the drugs reasonably (below 34k) when it is their funding paying for it to begin with. here's an idea, get rid of patents on life saving medicine and allow generics to enter the market......
Comment by: John-Manuel Andriote
Thu., Aug. 23, 2012 at 5:30 pm UTC
It' s obscene--and makes no medical, moral or economic sense--to charge such an outrageously inflated price for medicaiton that costs pennies to produce, especially when it means further burdening the federal and state programs that pay for HIV medications with taxpayer dollars. Big Pharma needs to get a clue that Americans aren't going to keep accepting the 'unspoken bargain' in which we are forced to pay more for prescription drugs than any other people in the world--after our tax dollars already pay for their research and development costs!
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy